A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results